-
Je něco špatně v tomto záznamu ?
The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors
G. Korinkova, K. Cwiertka, M. Paprskarova, P. Dzubak, M. Hajduch
Jazyk angličtina Země Slovensko
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
20099981
DOI
10.4149/neo_2010_02_161
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom farmakoterapie patologie radioterapie MeSH
- apoptóza účinky léků účinky záření MeSH
- buněčný cyklus účinky léků účinky záření MeSH
- cyklin-dependentní kinasy antagonisté a inhibitory metabolismus MeSH
- inhibitory proteinkinas farmakologie MeSH
- kinetin farmakologie MeSH
- lidé MeSH
- nádorové buňky kultivované účinky léků MeSH
- nádory plic farmakoterapie radioterapie MeSH
- průtoková cytometrie MeSH
- puriny farmakologie MeSH
- radiosenzibilizující látky farmakologie MeSH
- rentgenové záření MeSH
- western blotting MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Bohemine and roscovitine are the most important representatives of the group of compounds structurally derived from olomoucine. Biologically they function as inhibitors of cyclin-dependent kinases (CDKs), the key regulators of cell cycle, which is often disrupted in cancer cells resulting in uncontrollable proliferation. Bohemine and roscovitine have demonstrated their cytostatic and cytotoxic in vitro and also in vivo effects. Currently the phase II clinical trials for roscovitine are underway. The aim of the study was to evaluate the potential in vitro radiosensitising effect of bohemine (BOH) and roscovitine (ROS). Clonogenic survival assay and human lung adenocarcinoma cell line A549 were used. Tested schedules were: A-pretreatment, B-concomitant application and C-posttreatment. Concentrations corresponded to IC10, IC25 and IC50 for BOH/ROS (0.1-30 microM). The radiation doses were 1, 2 and 3 Gy. Flow cytometry and western blot analysis were used to characterize cell cycle distribution, BrdU incorporation and DNA repair processes. The highest in vitro radiosensitising effect of BOH/ROS was observed for Schedule A in all tested concentrations (SER(37%) 1.46-3.20). Cell cycle analysis showed an inclination towards G0/G1 delay 48 hours posttreatment and unaltered level of apoptosis. Changes in the DNA repair processes were observed - inhibition of DNA-PK kinase, inhibition of BrdU incorporation, strong and enduring induction of p21 protein and long-lasting phosphorylation of gammaH2AX(Ser139). Certain low concentration activities of BOH/ROS in monotherapy were detected, mainly the activation of DNA-PK kinase. The results demonstrated strong in vitro radiosensitising effect of BOH/ROS that is concentration and especially schedule dependent. The strong cytostatic effect of the pretreatment schedule is mediated through the inhibition/rearrangements of DNA repair processes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025269
- 003
- CZ-PrNML
- 005
- 20130129181521.0
- 007
- ta
- 008
- 120816s2010 xo f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2010_02_161 $2 doi
- 035 __
- $a (PubMed)20099981
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Kořínková, Gabriela $7 xx0087788 $u Laboratory of Experimental Medicine, Department of Pediatrics, Faculty of Medicine, Palacký University & Faculty Hospital in Olomouc, Olomouc, Czech Republic. gabriela.korinkova@seznam.cz
- 245 14
- $a The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors / $c G. Korinkova, K. Cwiertka, M. Paprskarova, P. Dzubak, M. Hajduch
- 520 9_
- $a Bohemine and roscovitine are the most important representatives of the group of compounds structurally derived from olomoucine. Biologically they function as inhibitors of cyclin-dependent kinases (CDKs), the key regulators of cell cycle, which is often disrupted in cancer cells resulting in uncontrollable proliferation. Bohemine and roscovitine have demonstrated their cytostatic and cytotoxic in vitro and also in vivo effects. Currently the phase II clinical trials for roscovitine are underway. The aim of the study was to evaluate the potential in vitro radiosensitising effect of bohemine (BOH) and roscovitine (ROS). Clonogenic survival assay and human lung adenocarcinoma cell line A549 were used. Tested schedules were: A-pretreatment, B-concomitant application and C-posttreatment. Concentrations corresponded to IC10, IC25 and IC50 for BOH/ROS (0.1-30 microM). The radiation doses were 1, 2 and 3 Gy. Flow cytometry and western blot analysis were used to characterize cell cycle distribution, BrdU incorporation and DNA repair processes. The highest in vitro radiosensitising effect of BOH/ROS was observed for Schedule A in all tested concentrations (SER(37%) 1.46-3.20). Cell cycle analysis showed an inclination towards G0/G1 delay 48 hours posttreatment and unaltered level of apoptosis. Changes in the DNA repair processes were observed - inhibition of DNA-PK kinase, inhibition of BrdU incorporation, strong and enduring induction of p21 protein and long-lasting phosphorylation of gammaH2AX(Ser139). Certain low concentration activities of BOH/ROS in monotherapy were detected, mainly the activation of DNA-PK kinase. The results demonstrated strong in vitro radiosensitising effect of BOH/ROS that is concentration and especially schedule dependent. The strong cytostatic effect of the pretreatment schedule is mediated through the inhibition/rearrangements of DNA repair processes.
- 650 _2
- $a adenokarcinom $x farmakoterapie $x patologie $x radioterapie $7 D000230
- 650 _2
- $a apoptóza $x účinky léků $x účinky záření $7 D017209
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a buněčný cyklus $x účinky léků $x účinky záření $7 D002453
- 650 _2
- $a cyklin-dependentní kinasy $x antagonisté a inhibitory $x metabolismus $7 D018844
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetin $x farmakologie $7 D007701
- 650 _2
- $a nádory plic $x farmakoterapie $x radioterapie $7 D008175
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a puriny $x farmakologie $7 D011687
- 650 _2
- $a radiosenzibilizující látky $x farmakologie $7 D011838
- 650 _2
- $a nádorové buňky kultivované $x účinky léků $7 D014407
- 650 _2
- $a rentgenové záření $7 D014965
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ćwiertka, Karel, $d 1961- $7 xx0018322
- 700 1_
- $a Paprskářová, Martina $7 xx0086519
- 700 1_
- $a Džubák, Petr $7 xx0080445
- 700 1_
- $a Hajdúch, Marián, $d 1969- $7 xx0050218
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 57, č. 2 (2010), s. 161-169
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20099981 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y m
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20130129181645 $b ABA008
- 999 __
- $a ok $b bmc $g 947311 $s 782615
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 57 $c 2 $d 161-169 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20120816/10/02